The goal with this series was to remove unnecessary complexity and focus purely on the practice learners actually ...

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. The company’s Ingrezza (valbenazine), approved to treat certain uncontrolled movement ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several ...

Fibre and product converting company Teijin Frontier has developed a new “multi-functional comfort” textile intended for use ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Create a Physics World account to get access to all available digital issues of the monthly magazine. Your Physics World ...

Daiichi Sankyo and GENESIS Pharma will distribute and commercialize quizartinib, brand name VANFLYTA, in 13 markets.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte(NASDAQ:PCVX), disposed of 9,743 shares in an open-market sale valued at approximately $454,891 according to the SEC Form 4 filing.